Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04393194
Other study ID # ZS-2164
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date May 24, 2020
Est. completion date September 1, 2022

Study information

Verified date May 2020
Source Peking Union Medical College Hospital
Contact Lan Zhu
Phone +86-69156874
Email zhu_julie@vip.sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this two-arm randomized clinical trial is to determine if in women desiring use of a pessary for pelvic organ prolapse (POP) and are successfully fit, if 1-year use and patient impression of improvement is superior in women using vaginal estrogen cream versus those using a vaginal placebo cream.


Description:

The study is a multi-center, randomized trial of women with symptomatic utero-vaginal or post-hysterectomy vaginal vault prolapse desiring non-surgical treatment with a pessary. This study will compare outcomes in women randomized to vaginal estrogen cream or vaginal placebo cream.

Women who meet the inclusion/exclusion criteria will be evaluated. A pessary (ring with support) will be fit by an experienced physician. After successful pessary fitting, they will be randomly divided into experimental active medication and control groups. The experimental group will start intravaginal estrogen cream, and the control group will start intravaginal estrogen-free cream. Then patients will be followed every 3months until 1year.

The purpose of this trial is to evaluate the effect of intravaginal estrogen use on pessary treatment for pelvic organ prolapse, including short-term and long-term use rate, patient impression of improvement, improvement in symptom-specific quality of life and complication incidence.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 420
Est. completion date September 1, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

1. Symptomatic POP, stage II, stage III or stage IV

2. Postmenopausal women (patients with serum FSH>40lu/L; or amenorrhea for 12 months)

3. Successfully fit with ring with support pessary

4. Ability to attend the clinical trial and follow-up

5. Patients and their families understand the study, are willing to participate for up to 1 year and can provide written informed consent

6. Willing and able to place vaginal cream

Exclusion Criteria:

1. Acute infection of internal genital tract

2. Hormone replacement therapy in recent 3 months

3. Suspected or untreated lower genital tract tumor

4. Genital fistula

5. Abnormally elevated intra-abdominal pressure (eg ascites, tumor, etc)

6. Life expectancy less than 1 year

7. Vaginal estrogen contraindications, including known or suspected estrogen dependent malignancies (endometrial carcinoma, melanoma), endometrial hyperplasia (thickness of endometrium=5mm), thrombophlebitis or thromboembolic disease, undiagnosed irregular vaginal bleeding, known or suspected breast cancer, allergy to any component of the estrogen cream and severe liver disease, breast cancer

8. The volume of post-voiding residual is more than 250ml. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vaginal Cream with Applicator [Dose Form]
Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of subjects using the pessary and have very much or much improvement on the patient impression of improvement questionnaire at 1 year between the vaginal estrogen group and the placebo group. Sustained wearing with satisfaction: continuous wearing is defined as the use of the pessary after successful fitting test. The continuous wearing time interval is from the start of wearing the pessary to cessation of pessary use.
PGI-I (patient global impression of improvement))is used to evaluate patient impression of improvement. PGI-I is divided into seven levels: very much better, much better, a little bit better, no change, a little bit worse, much worse and very much worse. The patient's response of" very much better" and" much better" is defined as a successful impression of improvement.
up to 1year after randomization
Secondary 1. Comparison of symptom specific distress (PFDI-20) at 6 months and one year in subjects using the pessary in the vaginal estrogen group and the placebo group at 1 year. Questionnaire survey: Relief of symptoms using validated instruments, Pelvic Floor Distress Inventory-20 ?PFDI-20 scores 0-300, The higher the score is, the more serious the symptoms of PFD are, the greater the impact on the life of the patients. up to 1year after randomization
Secondary 1. Comparison of symptom specific impact (PFIQ-7) at 6 months and one year in subjects using the pessary in the vaginal estrogen group and the placebo group at 1 year. Questionnaire survey: Relief of symptoms using validated instruments, pelvic floor impact questionnaire short form 7(PFIQ-7)?PFIQ-7 scores 0-300, the higher the severer negative influence on patient. up to 1year after randomization
Secondary 1. Comparison of sexual function (PISQ-12) at 6 months and one year in subjects using the pessary in the vaginal estrogen group and the placebo group at 1 year. Questionnaire survey: Relief of symptoms using validated instruments, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form(PISQ-12), PISQ-12 scores 0-48, the higher, the severer negative influence on patient. up to 1year after randomization
Secondary Comparison of the adverse events of subjects wearing a pessary in the vaginal estrogen group and the placebo group at 1 year. Complications will be asked and reported during each follow-up up to 1year after randomization
See also
  Status Clinical Trial Phase
Completed NCT03387202 - Laparoscopic Lateral Mesh Suspension for Pelvic Organ Prolapse N/A
Recruiting NCT04428320 - The Effect of Preemptive Levator Ani Injections on Pain After Pelvic Reconstructive Surgery N/A
Completed NCT02680145 - Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use N/A
Recruiting NCT04547816 - Efficacy of Conservative Treatment of Functional Defecatory Disorders in Females With Pelvic Organ Prolapse Phase 3
Completed NCT03421457 - Laparoscopic Lateral Suspension With Mesh & Sacrocervicopexy for the Treatment of Uterine Prolapse N/A
Withdrawn NCT01387685 - Treatment of Pelvic Organ Prolapse by PIVS Versus Surgeon Cut Mesh N/A
Withdrawn NCT01383291 - Prolift Versus IVS for Pelvic Floor Prolapse N/A
Completed NCT01392417 - Anterior Prolift Versus Posterior Prolift for Pelvic Floor Prolapse N/A